Welcome to LookChem.com Sign In|Join Free
  • or
BOC-L-GLUTAMIC ACID DIBENZYL ESTER is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

80963-14-0

Post Buying Request

80963-14-0 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

80963-14-0 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 80963-14-0 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 8,0,9,6 and 3 respectively; the second part has 2 digits, 1 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 80963-14:
(7*8)+(6*0)+(5*9)+(4*6)+(3*3)+(2*1)+(1*4)=140
140 % 10 = 0
So 80963-14-0 is a valid CAS Registry Number.

80963-14-0SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 17, 2017

Revision Date: Aug 17, 2017

1.Identification

1.1 GHS Product identifier

Product name dibenzyl (2S)-2-[(2-methylpropan-2-yl)oxycarbonylamino]pentanedioate

1.2 Other means of identification

Product number -
Other names BOC-L-GLUTAMIC ACID DIBENZYL ESTER

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:80963-14-0 SDS

80963-14-0Relevant academic research and scientific papers

SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF

-

Page/Page column 32-33, (2019/08/26)

Disclosed are compounds having potency in the modulation of NMDA receptor activity. Such compounds can be used in the treatment of conditions such as depression and related disorders as well as other disorders.

SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF

-

Page/Page column 77, (2018/03/09)

Disclosed are compounds having potency in the modulation of NMDA receptor activity. Such compounds can be used in the treatment of conditions such as depression and related disorders. Orally delivered formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.

Synthesis and pharmacological evaluation of side chain modified glutamic acid analogues of the neuroprotective agent glycyl-L-prolyl-L-glutamic acid (GPE)

Brimble, Margaret A.,Trotter, Nicholas S.,Harris, Paul W.R.,Sieg, Frank

, p. 519 - 532 (2007/10/03)

The synthesis of eight GPE* analogues, wherein the γ-carboxylic moiety of the glutamic residue has been modified, is described by coupling readily accessible N-benzyloxycarbonyl-glycyl-l-proline with various analogues of glutamic acid. Pharmacological evaluation of the novel compounds was undertaken to further understand the role of the glutamate residue on the observed neuroprotective properties of the endogenous tripeptide GPE.

Soluble alpha-amino acid salts in acetonitrile: practical technology for the production of some dipeptides.

Palomo, Claudio,Palomo, Antonio L,Palomo, Francisco,Mielgo, Antonia

, p. 4005 - 4008 (2007/10/03)

Alpha-amino acids are soluble in acetonitrile when treated with phosphazene bases. As a result, the protection/deprotection events that are usually required for peptide coupling reactions can be minimized. This is illustrated in the synthesis of the important angiotensin-converting enzyme (ACE) inhibitor enalapril. [reaction: see text]

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 80963-14-0